MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco-25-02187

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026

Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Oberstein Paul E, Hecht J Randolph, Raghav Kanwal, Pietrantonio Filippo, Arnold Dirk, Moreno Victor, Van Cutsem Eric, Malik Rozita Abdul, Hong Yong Sang, Lee Myung Ah, Yu-Li Su Harvey, Lee Jeeyun, Chandana Sreenivasa, Cruz-Correa Marcia, Yuan Ying, Ahmad Azura, Lai Kuan-Ming, Hsu Hung-Chih, Chen Eric Xueyu, Elez Elena, Lin Chia-Chi, Lopez Carlos, Prenen Hans, Roselló-Keränen Susana, Velez Hector, Yeh Yu-Min, Heinemann Volker, Eng Cathy, Beom Seung-Hoon, Tejpar Sabine, Chowdhury Sanjib, Lyu Xuesong, Kamat Medha, Curtin Joshua C, Patel Bharvin, Xie John, Bhattacharya Rianka, Schnepp Robert W, Yilmaz Emrullah, Iwasawa Ryota, Daksh Mahesh, Lorenzini Patricia, Thayu Meena, Baig Mahadi, Kim Han Sang, Han Sae-Won

СтатьяКлиническое исследование II фазыКлиническое исследование I фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Amivantamab, an EGFR-MET bispecific antibody with immune cell-directing activity, is approved in non-small cell lung cancer (NSCLC). Effective treatments are limited for chemorefractory metastatic colorectal cancer (mCRC).

METHODS

OrigAMI-1 (ClinicalTrials.gov identifier: NCT05379595) is a phase Ib/II study evaluating amivantamab monotherapy in chemorefractory (2-3 prior lines) mCRC. Participants had centrally confirmed RAS/BRAF/EGFR ectodomain wild-type status, without ERBB2/HER2 amplification. Participants with left-sided mCRC without (cohort A) or with (cohort B) prior anti-EGFR antibody treatment, or right-sided mCRC (cohort C) regardless of prior anti-EGFR treatment, received intravenous amivantamab 1,050 mg (1,400 mg for ≥80 kg) once every 2 weeks. The primary end point was objective response rate (ORR) per RECIST v1.1.

RESULTS

By October 31, 2024, 94 participants received amivantamab monotherapy (median follow-up, 11.9 months). The median age was 60 years, and 65% of participants were male, with a median of 2 prior lines (94%, prior bevacizumab). In left-sided cohorts, the ORR was 29% (5 of 17) in cohort A and 19% (10 of 54) in cohort B; the median duration of response (DoR) was 9.0 months and 6.1 months, and the median progression-free survival (PFS) was 5.7 months and 4.6 months, respectively. In the right-sided cohort, the ORR was 22% (10 of 23; 43% had prior anti-EGFR), the median DoR was 9.8 months, and the median PFS was 3.7 months. Most frequent treatment-related grade ≥3 adverse events (AEs) were rash (7%), dermatitis acneiform (4%), and hypoalbuminemia (4%). One participant discontinued amivantamab because of a treatment-related AE.

CONCLUSION

Amivantamab monotherapy demonstrated promising, durable antitumor activity in chemorefractory mCRC, regardless of prior anti-EGFR therapy and the primary tumor location. The amivantamab safety profile in mCRC is consistent with experience in NSCLC. Amivantamab plus chemotherapy is currently being explored in two phase III studies in first-line and second-line mCRCs.

Для цитирования: Oberstein Paul E, Hecht J Randolph, Raghav Kanwal, Pietrantonio Filippo, Arnold Dirk, Moreno Victor, Van Cutsem Eric, Malik Rozita Abdul, Hong Yong Sang, Lee Myung Ah, Yu-Li Su Harvey, Lee Jeeyun, Chandana Sreenivasa, Cruz-Correa Marcia, Yuan Ying, Ahmad Azura, Lai Kuan-Ming, Hsu Hung-Chih, Chen Eric Xueyu, Elez Elena, Lin Chia-Chi, Lopez Carlos, Prenen Hans, Roselló-Keränen Susana, Velez Hector, Yeh Yu-Min, Heinemann Volker, Eng Cathy, Beom Seung-Hoon, Tejpar Sabine, Chowdhury Sanjib, Lyu Xuesong, Kamat Medha, Curtin Joshua C, Patel Bharvin, Xie John, Bhattacharya Rianka, Schnepp Robert W, Yilmaz Emrullah, Iwasawa Ryota, Daksh Mahesh, Lorenzini Patricia, Thayu Meena, Baig Mahadi, Kim Han Sang, Han Sae-Won. Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. DOI: 10.1200/jco-25-02187.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.